- $1.01bn
- $608.91m
- 25
- 15
- 60
- 24
Annual cashflow statement for 89bio, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -49.5 | -90.1 | -102 | -142 | -367 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 4.3 | 10.2 | 10.3 | 12.2 | 13.7 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -1.04 | 3.25 | 10.6 | 0.657 | -14.5 |
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -46.2 | -76.8 | -81.1 | -129 | -368 |
| Capital Expenditures | -0.126 | -0.063 | -0.007 | -0.004 | -0.015 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -107 | 7.22 | -33.9 | -123 | -40.8 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -107 | 7.16 | -33.9 | -123 | -40.9 |
| Financing Cash Flow Items | -0.161 | 0 | -0.298 | -2.27 | -2.9 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 158 | 23.9 | 118 | 513 | 219 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 4.85 | -45.8 | 2.8 | 261 | -190 |